Summary: The text explores the use of gene editing technology CRISPR-Cas9 in modifying DNA to treat genetic diseases, with a focus on sickle cell anemia. It discusses the challenges faced in utilizing this technology, such as off-target effects, ethical concerns, and the need for long-term monitoring of patients. The potential benefits of gene editing in providing a one-time treatment for genetic disorders are highlighted, with advancements in clinical trials showing promise in effectively treating sickle cell disease. The article also addresses the importance of diversity in research participants to ensure the effectiveness of gene editing therapies across different populations. Despite these advancements, researchers emphasize the need for further studies and regulatory approvals to fully realize the potential of CRISPR-Cas9 in revolutionizing the treatment of genetic diseases.